Skip to main content

Advertisement

SpringerLink
Log in

Validated Method to Determine Quetiapine and Norquetiapine in Microsomal Matrix by LC MS–MS: Implication in Quetiapine Metabolism

  • Original
  • Published:
Chromatographia Aims and scope Submit manuscript

Abstract

A sensitive and selective LC–MS/MS method for the quantification of the atypical antipsychotic agent quetiapine and its metabolite norquetiapine (N-desalkyl quetiapine) was developed and validated. Following the protein precipitation technique, the analytes were separated using a reversed phase column with gradient elution. The compounds were ionized in the electrospray positive ionization (ESI+) ion source tandem MS detection in multiple reaction monitoring (MRM) mode. Calibration curves were generated by plotting the peak area ratio of quetiapine and norquetiapine to the IS clozapine for each calibration concentration. The method provides a linear response from a quantitation range of 2.3–452.9 nM (0.9–173.7 ng/mL) and 2.7–543.0 nM (1.0–200.0 ng/mL) for quetiapine and norquetiapine, respectively. Regression analysis showed a correlation coefficient greater than 0.999 and 0.991 for quetiapine and norquetiapine, respectively. To evaluate the metabolism of quetiapine by the cytochrome P450 in microsomes, the method has been subsequently employed. LC–MS/MS procedure has been carried out to determine increasing concentrations of both drugs in microsomal matrix obtained by a pool of mammalian liver microsomes BD UltraPoolTM Human Liver Microsomes (HLM 150).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Nemeroff C, Kinkead B, Goldstein J (2002) Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 63:5–11

    CAS  Google Scholar 

  2. Davis PC Chromatographia (2000) S-103

  3. Riedel M, Muller N, Strassnig M, Spellmann I, Severus E, Moller HJ (2007) Quetiapine in the treatment of schizophrenia and related disorders. Neuropsychiatr Dis Treat 3(2):219–235

    Article  CAS  Google Scholar 

  4. Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68(1):29–39

    Article  CAS  Google Scholar 

  5. Bakken GV, Rudberg I, Christensen H, Molden E, Refsum H, Hermann M (2009) Metabolism of quetiapine by cyp3a4 and cyp3a5 in presence or absence of cytochrome b5. Drug Metab Dispos 37(2):254–258

    Article  CAS  Google Scholar 

  6. Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB (2006) Effects of cytochrome p450 3a modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 61(1):58–69

    Article  CAS  Google Scholar 

  7. McIntyre RS, Soczynska JK, Woldeyohannes HO, Alsuwaidan M, Konarski JZ (2007) A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother 8(9):1211–1219

    Article  CAS  Google Scholar 

  8. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL (2008) N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-ht1a agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacol 33(10):2303–2312

    Article  CAS  Google Scholar 

  9. Zeneca Astra (2009) SeroquelXR® (quetiapine fumarate) extended release tablets highlights of prescribing information. AstraZeneca Pharmaceuticals LP Wilmington, DE 19850

    Google Scholar 

  10. Pira L, Strada M, Dalpiaz A, Pani L (2010) Ruolo del citocromo P450 nell’effetto antidepressivo della quetiapina. Therapy Perspect 13:13

    Google Scholar 

  11. De Vane C, Nemeroff C (2001) Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 40(7):509

    Article  Google Scholar 

  12. Lin SN, Chang Y, Moody DE, Foltz RL (2004) A liquid chromatographic-electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: application to study in vitro metabolism. J Anal Toxicol 28(6):443–448

    Article  CAS  Google Scholar 

  13. Kundlik ML, Kambli S, Shah V, Patel Y, Gupta S, Sharma R, Zaware B, Kuchekar S (2009) Chromatographia 1587

  14. Soma Raju IV, Raghuram P, Sriramulu J (2009) Development and validation of a new analytical method for the determination of related components in quetiapine hemifumarate. Chromatographia 70:545–550

    Article  CAS  Google Scholar 

  15. Khanvilkar Vineeta V, Chitnis Aditi P, Abhay S, Kadam Vilasrao J (2013) Development and validation of a bioanalytical method for determination of quetiapine from human plasma. IRJP 4(2)

  16. Pan RN Kuo BPC Pao LH J (2012) Chromatogr Science 277

  17. Nirogi R, Bhyrapuneni G, Kandikere V, Mudigonda K, Ajjala D, Mukkanti K (2008) Sensitive liquid chromatography tandem mass spectrometry method for the quantification of quetiapine in plasma. Biomed Chromatogr 22(10):1043–1055

    Article  CAS  Google Scholar 

  18. Barrett B, Holcapek M, Huclova J, Borek-Dohalsky V, Fejt P, Nemec B, Jelinek I (2007) Validated HPLC MS–MS method for determination of quetiapine in human plasma. J Pharm Biomed Anal 44(2):498–505

    Article  CAS  Google Scholar 

  19. Zhou Z, Li X, Li K, Xie Z, Cheng Z, Peng W, Wang F, Zhu R, Li H (2004) Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 802(2):257–262

    Article  CAS  Google Scholar 

  20. Davis PC, Bravo O, Gehrke M, Azumaya CT (2010) Development and validation of an LC MS–MS method for the determination of quetiapine and four related metabolites in human plasma. J Pharm Biomed Anal 51(5):1113–1119

    Google Scholar 

Download references

Acknowledgments

The present study was generously supported by a grant from AstraZeneca S.p.A. The authors would like to thank Dr. Ignazia Mocci for her precious assistance in the management and control of standard procedures.

Author information

Authors and Affiliations

  1. Consorzio El-Pro, Edificio 5, Loc. Piscinamanna, 09010, Pula (CA), Italy

    Giuseppe Peddio

  2. Consiglio Nazionale delle Ricerche, Istituto di Farmacologia Traslazionale UOS Cagliari, Edificio 5, Loc. Piscinamanna, 09010, Pula (CA), Italy

    Giuseppe Peddio, Barbara Pittau, Ilaria Manca & Luca Pani

  3. Neuroscienze PharmaNess Scarl, Edificio 5, Loc. Piscinamanna, 09010, Pula (CA), Italy

    Barbara Pittau, Roberta Salis & Luigi Pira

Authors
  1. Giuseppe Peddio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara Pittau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ilaria Manca
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roberta Salis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luca Pani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Luigi Pira
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luigi Pira.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peddio, G., Pittau, B., Manca, I. et al. Validated Method to Determine Quetiapine and Norquetiapine in Microsomal Matrix by LC MS–MS: Implication in Quetiapine Metabolism. Chromatographia 77, 75–82 (2014). https://doi.org/10.1007/s10337-013-2576-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10337-013-2576-6

Keywords

Search

Navigation